insider sale

Maze Therapeutics CSBO Atul Dandekar sold 7,500 shares for $190,000 under a pre-planned trading agreement, concurrent with positive phase 2 trial results.

Marqeta director sold half his stake ($78K) in April transaction; analysts note insider sales typically reflect personal planning, not company concerns.

Visteon's Chief People Officer sold $477K in stock after 42% rally, retaining 6,000 shares amid peak valuations.

Pacira CFO sold $326K in stock via pre-planned trading arrangement before Q1 earnings beat, with shares appreciating 12% in April.

Pharvaris director's modest 1.80% stock sale matters less than upcoming Phase 3 data and FDA submission catalysts arriving in 2026.

LifeStance Health director Robert Bessler sold 69,899 shares worth $492,000, retaining over 2.7 million shares. Analysts remain bullish given strong 2025 performance.

Sionna director sells $2.5M in stock (2% of holdings) during 215% surge; $310M cash position supports pipeline through 2028.

Oil-Dri director sells $102K in stock after 75% surge and record revenue, marking typical profit-taking amid margin pressures.

Aehr Test Systems founder offloads $1.77M in shares as stock soars 1,076% annually. Stretched valuation raises concerns despite strong AI semiconductor demand.

IMAX CEO Richard Gelfond sold $2.8M in shares via routine options exercise. Strong 2025 performance and transaction structure suggest standard management, not a red flag.

RSI director sells $1.1M stake via routine plan as 2025 revenue hits $1.1B and net income surges to $74M from $7.2M, with stock doubling.

Revolve Group Co-CEO Michael Mente sold 16,000 shares for $414,000, retaining majority control. Company reports robust Q4 results with 10% sales growth and 58% net income surge.

Aehr director sold $661K in stock amid $41M AI order. Strong bookings mask declining year-over-year revenue; 55x P/S valuation suggests peak sentiment.

Dianthus Therapeutics CFO Ryan Savitz sold 8,224 shares for $739,000 on April 9, 2026, reducing direct holdings to zero while retaining substantial options.

$ADPT's President/COO sold $826K in shares via option exercise while retaining 408K shares. MRD revenue grew 46%; Medicare coverage expansion supports growth outlook.

Nuvation Bio's Chief Regulatory Officer sold 200,000 shares for $904K but retained 53,000 shares and 700,000 options, suggesting routine profit-taking rather than lost confidence.

Vir Biotechnology CEO Marianne De Backer sold 72,559 shares worth $664,350, representing 6.76% of holdings. Sale aligns with historical patterns amid company's positive momentum.

Lightwave Logic PFO sells $207K in shares after 939% rally. $1.58B market cap relies on minimal $106K revenue.

Beam Therapeutics CEO John Evans sold 30,078 shares for $739K via pre-planned tax obligation. Strong 2025 revenue growth and $1.2B cash reserves indicate company health.

Adaptive Biotech insider sold $554K in shares via routine plan; company posted 55% revenue growth and dramatically narrowed losses, signaling operational inflection.